Understanding Chemotherapy and Its Effects on the Eyes
Chemotherapy is designed to target and destroy rapidly dividing cells throughout the body. While this makes it effective against cancer, many healthy cells in the body also divide quickly, including those on the surface of the eye and in the glands that produce tears. Because chemotherapy drugs cannot perfectly distinguish between cancerous cells and healthy rapidly dividing cells, the eyes often become an unintended casualty of treatment.
The TFOS DEWS III report, a major international review of dry eye science, thoroughly documents the toxic effects of systemic cancer treatments on the ocular surface. According to this body of research, chemotherapy agents are among the most destructive causes of iatrogenic dry eye. Iatrogenic means the condition is caused by a medical treatment rather than developing on its own. Understanding this connection is important because dry eye symptoms during chemotherapy are not just an inconvenience. They can significantly affect comfort, vision, and quality of life during an already difficult time.
Chemotherapy drugs affect the eyes through two distinct and damaging pathways. The first involves direct toxicity to the lacrimal glands, which are the small glands located above each eye that produce the watery (aqueous) layer of the tear film. Chemotherapy agents are toxic to the cells within these glands, severely depressing their ability to produce tears. This leads to a significant reduction in the volume of fluid available to keep the eye surface moist.
The second pathway is even more unusual and harmful. The body actively secretes chemotherapy drugs into the tears themselves. This means the toxic medication is not just reducing tear production. It is also present in whatever tears are still being made. When these chemotherapy-laden tears wash over the surface of the eye, they poison the delicate cells of the cornea (the clear front window of the eye) and the conjunctiva (the thin tissue lining the inner eyelids and covering the white of the eye). This causes widespread cellular damage and prevents the normal process of tissue renewal that keeps the eye surface healthy.
Clinical observations documented in the TFOS DEWS III report reveal that chemotherapy-induced dry eye often presents differently and more severely than other forms of dry eye. Patients undergoing chemotherapy frequently exhibit severe ocular surface staining, which is a test where a special dye is applied to the eye to reveal areas of cellular damage. The extent of staining in chemotherapy patients is often significantly greater than in patients with other types of dry eye, reflecting the direct toxic effects of the medication on the eye's surface cells.
Patients also commonly report profound burning sensations. This is caused by the combination of reduced tear volume, concentrated (hyperosmolar) tears, and the direct chemical irritation from the chemotherapy agents present in the tear film. The burning is often more intense than what patients with other forms of dry eye experience because the eye surface is being chemically aggravated by the medication itself.
One of the more serious complications associated with chemotherapy-related dry eye is canalicular stenosis. The canaliculi are the tiny drainage channels located near the inner corner of each eyelid that normally carry tears from the eye surface into the nasal passages. When chemotherapy drugs are secreted into the tears, these toxic tears flow through the canaliculi on their way to draining. Over time, the constant exposure to these chemical agents can cause the tissue lining the canaliculi to become inflamed, scarred, and eventually narrowed or completely closed.
Canalicular stenosis can cause persistent tearing (epiphora) because the tears have no normal pathway to drain. Ironically, patients may experience both dry eye symptoms and excessive tearing at the same time. The eye surface remains dry and damaged because the tears being produced are toxic and insufficient, while the blocked drainage causes overflow tearing down the cheeks.
While many chemotherapy drugs can affect the eyes, certain agents are more frequently associated with ocular surface damage. The TFOS DEWS III report specifically identifies several systemic chemotherapeutic agents as particularly toxic to the tear system and ocular surface. These drugs belong to different classes of chemotherapy and are used to treat a wide variety of cancers.
The severity of dry eye can vary depending on which chemotherapy agent is used, the dose, the duration of treatment, and whether the patient is receiving a combination of drugs. Combination chemotherapy regimens may compound the toxic effects on the eyes because multiple agents are simultaneously attacking the tear-producing glands and the ocular surface.
Chemotherapy-induced dry eye is distinct from most other forms of dry eye in one critical way. In typical medication-related dry eye, the drug reduces tear production or changes tear composition, but the tears themselves are not harmful. In chemotherapy-related dry eye, the tears become actively toxic. This means that the standard approach of simply retaining tears on the eye surface may not be the best strategy. In some situations, keeping toxic tears in contact with the eye for longer periods could actually worsen the damage rather than help. This unique characteristic fundamentally changes how eye care providers approach management.
Who Is Most at Risk for Chemotherapy-Related Dry Eye
The intensity and length of chemotherapy treatment directly influence the risk and severity of dry eye. Higher doses of chemotherapy deliver more toxic agents to the lacrimal glands and create higher concentrations of the drug in the tear film. Longer treatment courses mean the eyes are exposed to these damaging effects over a more extended period, allowing cumulative damage to build up in the glands, the drainage channels, and the surface cells of the eye.
Many cancer treatment protocols involve multiple chemotherapy drugs given together or in sequence. When more than one agent is affecting the tear system simultaneously, the combined toxic effect on the eyes can be significantly greater than any single drug would produce alone. Patients on combination regimens should be particularly attentive to changes in eye comfort and should inform their oncology and eye care teams about any new symptoms.
Tear production naturally decreases with age. When the age-related decline in lacrimal gland function is combined with the toxic effects of chemotherapy, the resulting reduction in tear volume and quality can be severe. Older adults undergoing chemotherapy should be proactive about eye care and consider a baseline eye evaluation before starting treatment.
Patients who already experience dry eye symptoms before beginning chemotherapy are at heightened risk for significant worsening during treatment. The existing imbalance in their tear film means they have less reserve capacity to absorb the additional stress that chemotherapy places on the tear system. If you have a history of dry eye and are preparing for chemotherapy, discussing a proactive management plan with your eye care provider before treatment begins can help minimize the impact.
Women are at higher baseline risk for dry eye disease due to hormonal factors, particularly those associated with menopause. When chemotherapy is added to this existing vulnerability, the combined effect can lead to more severe symptoms. Some chemotherapy regimens can also induce early menopause, which further compounds the hormonal contribution to dry eye.
Contact lenses depend on a healthy tear film to stay comfortable and functional. During chemotherapy, the reduced tear volume and the presence of toxic agents in the tears can make contact lens wear extremely uncomfortable and potentially harmful to the eye surface. Many patients find they need to temporarily switch to glasses during treatment. Your eye care provider can guide you on the safest approach for your situation.
Managing Dry Eye During and After Chemotherapy
The TFOS DEWS III management algorithm emphasizes that care for chemotherapy-related dry eye should be aggressive and, whenever possible, preventative rather than reactive. Starting a protective eye care routine before or at the very beginning of chemotherapy can help reduce the severity of ocular surface damage before it becomes entrenched. Waiting until symptoms are severe makes the condition harder to manage and may allow lasting damage to develop.
If you are about to begin chemotherapy, scheduling an evaluation with your eye care provider beforehand gives them a chance to assess your baseline tear function. This baseline makes it much easier to detect changes during treatment and allows your care team to intervene early.
The cornerstone of managing chemotherapy-related dry eye is frequent use of preservative-free artificial tears. The TFOS DEWS III algorithm specifically recommends that oncology patients flush their eyes regularly with these drops. The goal is twofold. First, the drops add much-needed moisture to an eye surface that is receiving far less aqueous fluid from the damaged lacrimal glands. Second, and perhaps more importantly, frequent application of artificial tears helps dilute and physically wash away the toxic chemotherapy agents that are being secreted into the tear film.
This flushing action is critical because it reduces the concentration of harmful chemicals in contact with the delicate corneal and conjunctival cells. The more frequently the drops are used, the lower the overall exposure of the eye surface to these toxic agents. Your eye care provider can recommend a specific schedule, but many patients benefit from applying drops every one to two hours during active treatment.
In most types of dry eye, punctal plugs are a helpful treatment. These tiny devices block the tear drainage openings to keep tears on the eye surface longer. However, chemotherapy-related dry eye presents a unique situation. Because the tears contain toxic chemotherapy agents, blocking the drainage pathway could potentially trap these harmful chemicals on the eye surface for a longer period, increasing rather than decreasing the damage.
The TFOS DEWS III report acknowledges this concern, noting that in severe cases of chemotherapy-related dry eye, punctal occlusion (plugging the tear drains) may be approached with caution to avoid pooling toxic tears on the eye surface. Your eye care provider will carefully evaluate whether punctal plugs are appropriate for your specific situation, weighing the benefits of retaining moisture against the risks of prolonged toxic exposure.
Environmental modifications can meaningfully reduce the burden on your eyes during chemotherapy. Using a humidifier at home adds moisture to the air and slows tear evaporation. Wearing wraparound glasses or moisture chamber glasses outdoors can shield your eyes from wind and dry air, creating a more humid microenvironment around the eye surface.
Avoiding direct airflow from fans, air conditioning, and heating vents helps preserve whatever moisture is present on the eye surface. Reducing screen time or taking frequent breaks during reading and computer use gives your tear film a chance to refresh. The 20-20-20 rule is a simple guideline: every 20 minutes, look at something 20 feet away for 20 seconds to encourage blinking and reduce eye surface exposure.
Regular comprehensive eye exams are especially important during and after chemotherapy. At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team evaluates the health of your tear film, monitors for ocular surface damage, and checks for complications such as canalicular stenosis. These detailed assessments allow your care team to adjust your management plan as treatment progresses and to detect early signs of complications before they become severe.
After chemotherapy ends, continued monitoring remains important. Some forms of damage, particularly canalicular stenosis, may not fully manifest until weeks or months after the final treatment cycle. Ongoing follow-up ensures that any delayed complications are caught and addressed promptly.
Effective management of chemotherapy-related dry eye works best when your oncology team and your eye care provider communicate with each other. Your oncologist understands the details of your treatment regimen and can provide information about which agents are most likely to affect the eyes. Your eye care provider can use this information to tailor your dry eye management plan, anticipate potential complications, and monitor for specific signs of drug-related toxicity.
Keeping both teams informed about changes in your symptoms, your treatment schedule, and any adjustments to your medications helps ensure that your eye care is fully coordinated with your cancer treatment. Do not hesitate to mention eye discomfort to your oncologist or to share your treatment details with your eye care provider.
Frequently Asked Questions
Many patients experience improvement in their dry eye symptoms after chemotherapy is completed, as the toxic agents are cleared from the body and the lacrimal glands begin to recover. However, the timeline for recovery varies widely. Some patients see improvement within weeks, while others may take months. In some cases, particularly when canalicular stenosis or significant gland damage has occurred, some degree of dry eye may persist and require ongoing management. Regular follow-up with your eye care provider after treatment helps track your recovery.
Yes, a pre-treatment eye evaluation is highly recommended. Establishing a baseline measurement of your tear production and overall eye surface health before chemotherapy begins gives your eye care provider a reference point for detecting changes during treatment. It also allows you to start a protective routine of preservative-free artificial tears and environmental modifications right away, which can help reduce the severity of dry eye symptoms during treatment.
Contact lens wear during chemotherapy can be problematic. The reduced tear volume means there is less fluid to keep the lens hydrated and comfortable. More importantly, the presence of chemotherapy agents in the tear film means that a contact lens could trap these toxic chemicals against the surface of the eye, prolonging exposure and increasing the risk of damage. Many patients find it safer and more comfortable to switch to glasses during treatment. Your eye care provider can help you determine the best approach based on your specific treatment and eye health.
The frequency depends on the severity of your symptoms and the specific chemotherapy regimen you are receiving. Many patients benefit from applying preservative-free artificial tears every one to two hours during active treatment to maintain adequate flushing of the eye surface. Your eye care provider can recommend a schedule tailored to your needs. The key is to use them consistently throughout the day rather than waiting until symptoms become uncomfortable, as the goal is to dilute and remove toxic agents before they cause significant damage.
Burning sensations during chemotherapy are a common symptom of chemotherapy-related dry eye and are usually caused by the combination of reduced tear volume, concentrated tears, and the direct chemical irritation from chemotherapy agents in the tear film. While burning is expected and treatable, it is important to report any eye symptoms to your eye care provider. Severe or sudden changes in vision, intense pain, or significant redness could indicate a more serious issue that needs prompt attention.
The primary difference is that in chemotherapy-related dry eye, the tears themselves become toxic. In most other forms of dry eye, the issue is either insufficient tear production or excessive tear evaporation, but the tears that are present are not harmful. Because chemotherapy agents are actively secreted into the tear film, they damage the eye surface with every blink. This means management strategies must focus not just on adding moisture but on actively flushing away the toxic components in the tears. This unique characteristic also affects decisions about treatments like punctal plugs, which may need to be used with more caution than in other forms of dry eye.